MX2018005145A - Terapia genetica. - Google Patents

Terapia genetica.

Info

Publication number
MX2018005145A
MX2018005145A MX2018005145A MX2018005145A MX2018005145A MX 2018005145 A MX2018005145 A MX 2018005145A MX 2018005145 A MX2018005145 A MX 2018005145A MX 2018005145 A MX2018005145 A MX 2018005145A MX 2018005145 A MX2018005145 A MX 2018005145A
Authority
MX
Mexico
Prior art keywords
genetic therapy
factor
vector
aav
adeno
Prior art date
Application number
MX2018005145A
Other languages
English (en)
Other versions
MX366343B (es
Inventor
GROENDAHL Christian
Funnell Tim
Hollowood Chris
Original Assignee
Syncona Investment Man Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55130363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018005145(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Syncona Investment Man Limited filed Critical Syncona Investment Man Limited
Publication of MX2018005145A publication Critical patent/MX2018005145A/es
Publication of MX366343B publication Critical patent/MX366343B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1725—Complement proteins, e.g. anaphylatoxin, C3a or C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)

Abstract

Un vector viral adeno-asociado (AAV), el cual comprende una secuencia de nucleótidos que codifica el Factor I o el Factor H, o un fragmento o derivado de los mismos. El vector es útil para el tratamiento o la prevención de un trastorno del ojo mediado por el complemento.
MX2018005145A 2015-10-28 2016-10-27 Terapia genetica. MX366343B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1519086.1A GB201519086D0 (en) 2015-10-28 2015-10-28 Gene Therapy
PCT/GB2016/053343 WO2017072515A1 (en) 2015-10-28 2016-10-27 Gene therapy

Publications (2)

Publication Number Publication Date
MX2018005145A true MX2018005145A (es) 2018-08-09
MX366343B MX366343B (es) 2019-07-05

Family

ID=55130363

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005145A MX366343B (es) 2015-10-28 2016-10-27 Terapia genetica.

Country Status (19)

Country Link
US (3) US20190255193A1 (es)
EP (3) EP3360890B1 (es)
JP (3) JP7126944B2 (es)
KR (1) KR102922606B1 (es)
CN (4) CN117343960A (es)
AU (3) AU2016344523B2 (es)
CA (1) CA3002125A1 (es)
DK (2) DK3360890T3 (es)
ES (2) ES2828050T3 (es)
GB (1) GB201519086D0 (es)
HK (1) HK1248723B (es)
IL (3) IL304084B1 (es)
MX (1) MX366343B (es)
NO (1) NO3262066T3 (es)
PL (2) PL3360890T3 (es)
RU (1) RU2740038C2 (es)
SG (1) SG11201802934WA (es)
WO (1) WO2017072515A1 (es)
ZA (1) ZA201802462B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10988519B2 (en) 2015-09-24 2021-04-27 The Trustees Of The University Of Pennsylvania Composition and method for treating complement-mediated disease
GB201519086D0 (en) * 2015-10-28 2015-12-09 Syncona Partners Llp Gene Therapy
IL322403A (en) 2016-04-15 2025-09-01 Univ Pennsylvania Preparations for the treatment of wet age-related macular degeneration
GB201608046D0 (en) * 2016-05-09 2016-06-22 Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The Treatment of complement-mediated disorders
TWI820034B (zh) * 2017-07-31 2023-11-01 香港商映像生物有限公司 眼部疾病之細胞模式及用於眼部疾病的療法
CN111788311A (zh) * 2017-10-20 2020-10-16 双子治疗公司 用于治疗年龄相关性黄斑变性的组合物和方法
US12558434B2 (en) 2018-02-20 2026-02-24 The Trustees Of The University Of Pennsylvania Compositions for treatment of wet age-related macular degeneration
WO2020077091A1 (en) * 2018-10-10 2020-04-16 Wisconsin Alumni Research Foundation Kir 7.1 gene therapy vectors and methods of using the same
US20210371480A1 (en) * 2018-10-23 2021-12-02 Gemini Therapeutics Inc. Compositions and methods for treating age-related macular degeneration and other diseases
GB201821082D0 (en) * 2018-12-21 2019-02-06 Gyroscope Therapeutics Ltd Combination of complement factors i and h, and vector encoding thereof
GB201821089D0 (en) * 2018-12-21 2019-02-06 Gyroscope Therapeutics Ltd Codon-optimised complement factor I
EP3946467A1 (en) * 2019-04-03 2022-02-09 REGENXBIO Inc. Gene therapy for eye pathologies
CA3153963A1 (en) * 2019-09-09 2021-03-18 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of restoring lysosomal function of retinal pigment epithelial cells by activation of tfeb
JP2023529497A (ja) 2020-06-14 2023-07-10 バーテックス ファーマシューティカルズ インコーポレイテッド 補体因子ｉ関連組成物および方法
GB202009741D0 (en) 2020-06-25 2020-08-12 Freeline Therapeutics Ltd Polynucleotide
US20220106611A1 (en) * 2020-09-09 2022-04-07 Homology Medicines, Inc. Vectorized antibodies and uses thereof
JPWO2022092294A1 (es) 2020-10-30 2022-05-05
GB202018320D0 (en) * 2020-11-20 2021-01-06 Univ Newcastle Methods of producing recombinant complement proteins
WO2023079297A1 (en) 2021-11-04 2023-05-11 Freeline Therapeutics Limited Mutant complement factor i variants with increased activity
EP4470563A4 (en) 2022-01-25 2026-01-14 Asagi Labs INNOVATIVE THERAPY AND PREVENTION TO ELIMINATE AGING-RELATED DISORDERS, PARTICULARLY SARCOPENIA

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
US6759237B1 (en) 1998-11-05 2004-07-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
GB0009760D0 (en) 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
KR20060031618A (ko) * 2003-06-10 2006-04-12 엔에스진 에이/에스 뉴블라스틴 분비 증진 방법
CA2597411C (en) 2005-02-14 2014-08-12 University Of Iowa Research Foundation Use of complement factor h polymorphisms in treatment and diagnosis of age-related macular degeneration
WO2007047995A2 (en) * 2005-10-21 2007-04-26 Catalyst Biosciences, Inc. Modified proteases that inhibit complement activation
EP2044111B1 (en) 2006-06-21 2014-08-13 MUSC Foundation For Research Development Targeting complement factor h for treatment of diseases
US20100120665A1 (en) 2007-03-01 2010-05-13 Advanced Vision Therapies, Inc. Treatment of diseases characterized by inflammation
CN101657097A (zh) * 2007-03-01 2010-02-24 先进视觉疗法公司 以炎症为特征的疾病的治疗
EP2623605B1 (en) 2007-04-09 2018-11-28 University of Florida Research Foundation, Inc. RAAV vector compositions having tyrosine-modified capsid proteins and methods for use
GB0816702D0 (en) * 2008-09-12 2008-10-22 Trinity College Dublin Complement proteins
GB0904427D0 (en) * 2009-03-13 2009-04-29 Lachmann Peter Treatment of diseases related to hyperactivity of the complement system
TWI702955B (zh) * 2012-05-15 2020-09-01 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒（ａａｖ）ｓｆｌｔ-１治療老年性黃斑部退化（ａｍｄ）
HK1218300A1 (zh) * 2013-01-23 2017-02-10 Musc Foundation For Research Development 基於天然抗體的靶向結構體及其應用
US20140234275A1 (en) 2013-02-15 2014-08-21 Jason Williams Method for treating als via the increased production of factor h
EP2986310B1 (en) * 2013-04-17 2020-08-05 Genzyme Corporation Compositions for treating and preventing macular degeneration
EP3013946B8 (en) * 2013-06-28 2019-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for expressing a polynucleotide of interest in the retina of a subject
GB201403684D0 (en) * 2014-03-03 2014-04-16 King S College London Vector
GB201519086D0 (en) * 2015-10-28 2015-12-09 Syncona Partners Llp Gene Therapy
GB201608046D0 (en) * 2016-05-09 2016-06-22 Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The Treatment of complement-mediated disorders

Also Published As

Publication number Publication date
AU2016344523A1 (en) 2018-06-14
EP3262066B2 (en) 2023-06-07
DK3262066T4 (da) 2023-08-21
CN116370655A (zh) 2023-07-04
EP3786176A1 (en) 2021-03-03
CN108431030A (zh) 2018-08-21
AU2025200979A1 (en) 2025-03-06
NO3262066T3 (es) 2018-07-07
BR112018008731A8 (pt) 2020-03-31
CN116271104A (zh) 2023-06-23
EP3262066B1 (en) 2018-02-07
US20190255193A1 (en) 2019-08-22
PL3262066T5 (pl) 2023-10-30
IL258806A (en) 2018-06-28
JP7126944B2 (ja) 2022-08-29
JP2022141670A (ja) 2022-09-29
US20230277689A1 (en) 2023-09-07
AU2016344523B2 (en) 2022-03-17
RU2018118954A (ru) 2019-12-02
CA3002125A1 (en) 2017-05-04
AU2022203675B2 (en) 2025-03-06
ZA201802462B (en) 2021-01-27
KR102922606B1 (ko) 2026-02-03
PL3262066T3 (pl) 2018-07-31
IL284577A (en) 2021-08-31
SG11201802934WA (en) 2018-05-30
DK3360890T3 (da) 2020-11-02
ES2666204T5 (es) 2023-11-03
ES2666204T3 (es) 2018-05-03
IL284577B1 (en) 2023-08-01
EP3360890B1 (en) 2020-10-07
DK3262066T3 (en) 2018-05-22
CN117343960A (zh) 2024-01-05
BR112018008731A2 (en) 2018-11-06
WO2017072515A1 (en) 2017-05-04
IL304084B1 (en) 2025-11-01
IL304084A (en) 2023-08-01
RU2740038C2 (ru) 2020-12-30
RU2018118954A3 (es) 2020-03-13
MX366343B (es) 2019-07-05
EP3360890A1 (en) 2018-08-15
ES2828050T3 (es) 2021-05-25
US20250319210A1 (en) 2025-10-16
JP2024156706A (ja) 2024-11-06
IL258806B (en) 2021-07-29
HK1248723B (en) 2019-11-22
CN108431030B (zh) 2023-10-20
EP3262066A1 (en) 2018-01-03
KR20180066247A (ko) 2018-06-18
AU2022203675A1 (en) 2022-06-16
JP2018537122A (ja) 2018-12-20
PL3360890T3 (pl) 2020-12-28
GB201519086D0 (en) 2015-12-09
IL284577B2 (en) 2023-12-01

Similar Documents

Publication Publication Date Title
MX2018005145A (es) Terapia genetica.
CL2016002333A1 (es) Terapia genica para la retinitis pigmentaria.
CL2018002054A1 (es) Genes del factor viii optimizados.
CL2017003096A1 (es) Vectores virales adenoasociados para el tratamiento de mucopolisacaridosis
CL2019001224A1 (es) Composiciones de células t con car anti--bcma.
CL2018001299A1 (es) Vectores virales que codifican variantes de la fviii recombinante con expresión aumentada para la terapia genetica de la hemofilia a.
CL2018001522A1 (es) Focalización de péptidos para dirigir virus adenoasociados (aavs)
MX2019004500A (es) Terapia de combinación para la inhibición de componente de complemeto (c3).
CR20160555A (es) Vectores de aav para la terapia génica de la retina y el snc
MX2017014443A (es) Adeno-asociado para administracion terapeutica al sistema nervioso central.
BR112017002332A2 (pt) terapia de combinação para o tratamento de um paramixovírus
AR100419A1 (es) Vectores de virus adenoasociados para el tratamiento de trastornos de almacenamiento lisosómico
GT201600233A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
MX2016005017A (es) Metodos para el tratamiento de condiciones asociadas con la activacion del complemento dependiente de masp-2.
EA201692537A1 (ru) Замещенные нуклеозиды, нуклеотиды и их аналоги
CL2017001292A1 (es) 4-oxo-3,4-dihidro-1,2,3-benzotraizinas como moduladores de gpr139
MX2016009965A (es) Produccion de alta titulacion de vectores virales adenoasociados.
MX2017010292A (es) Promotor de epitelio del pigmento retinal 65 (rpe65) optimizado y secuencias codificantes.
MX376201B (es) Compuestos inhibidores de metaloenzima.
BR112018001853A2 (pt) métodos para tratamento de um distúrbio e para melhoria do tratamento de um distúrbio
MX2016000095A (es) Transtornos neurodegenerativos.
MX2017003426A (es) Vectores virales adeno-asociados para tratar glaucoma de miocilina (myoc).
CL2018001301A1 (es) Vectores virales que codifican variantes fviii recombinante con expresión aumentada para la terapia genetica de la hemofilia a.
CL2017000087A1 (es) Un proceso novedoso para la purificación de rhu-gcsf
MX2018004542A (es) Neoepítopos virales y sus usos.

Legal Events

Date Code Title Description
FG Grant or registration